Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s): CLAZF

Healthcare

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.

TSXV:CLAS.H - Post by User

Claritas Pharmaceuticals Inc > Kly ‘s ceo and board is recommending that kly buys a company

<< Previous

Bullboard Posts

Next >>

Post by edroseon Jun 01, 2020 5:24pm

194 Views

Post# 31098575

Kly ‘s ceo and board is recommending that kly buys a company

Which as only one very early product not even close to being approved and we don't have the money to do the research on r107 and Barca funding is not even close to being approved
where will kly find the money we can't even do research on our product that only needs phase3 to be done

how does this make sense this is like the stero deal

<< Previous

Bullboard Posts

Next >>

How a junior advances one of the largest undeveloped diamond projects